Flortaucipir (18F) — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

4 Recruiting

4 Completed trials

6 Sponsors

5 Countries

Phase III

Phase II/III

Phase II

Phase I/II

Phase III: 1 Phase II/III: 3 Phase II: 5 Phase I/II: 1

Oversight events:

2 temporary halts across 1 trial

View oversight register →

Indications tested

Dementia Alzheimer's type 2

Sponsors using this IMP

Eli Lilly & Co. 3 Amsterdam UMC Stichting 2 Institut National De La Sante Et De La Recherche Medicale 2 Amsterdam UMC 1 Centre Hospitalier Universitaire De Nantes 1 F. Hoffmann-La Roche AG 1

All trials

10 total

MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A MRI/TEP STUDY Pending

2024-519995-20-00 Phase II/III 1 country Institut National De La Sante Et De La Recherche Medicale
CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strat… Pending

2025-523264-21-00 Phase II/III 1 country Institut National De La Sante Et De La Recherche Medicale
Synaptic density and tau pathology in Alzheimer’s disease Recruiting

2024-517636-22-00 Phase II 1 country Amsterdam UMC Stichting
Biomarkers of the locus coeruleus nucleus: links with early tau pathology, cognition and AD risk. LocusTau Recruiting

2023-507668-38-00 Phase II 1 country Centre Hospitalier Universitaire De Toulouse
Tau PET imaging in cognitively normal elderly subjects: A twin approach Recruiting

2024-517634-17-01 Phase II 1 country Amsterdam UMC Stichting
TAP-TAU Recruiting

2023-505430-10-00 Phase II/III 1 country Amsterdam UMC
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5) Ended

2025-522340-40-00 Phase III 2 countries Eli Lilly & Co.
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO712620… Ended

2023-509678-52-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer’s Disease Ended

2024-512295-36-00 Phase II 1 country Eli Lilly & Co.
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended

2023-507303-55-00 Phase II 3 countries Eli Lilly & Co.

Showing 1–10 of 10 trials

← All drugs A–Z